Form 4: Trevi Therapeutics Director Michael Heffernan Granted 45,000 Stock Options

Trevi Therapeutics, Inc. Director Michael Thomas Heffernan was granted 45,000 nonstatutory stock options with an exercise price of $6.25 per share, set to vest over approximately one year or by the next annual meeting.

Summary

• Michael Thomas Heffernan, a Director of Trevi Therapeutics, Inc. (TRVI), was granted 45,000 nonstatutory stock options.
• The options have an exercise price of $6.25 per share.
• The grant date for these options was June 11, 2025.
• The options are scheduled to fully vest on the earlier of (i) the first anniversary of the grant date (June 11, 2026) or (ii) the date of the next annual meeting of stockholders of Trevi Therapeutics, Inc. following the grant date.
• Vesting is subject to Mr. Heffernan's continued service as a director, employee, or consultant of the Issuer.
• The options have an expiration date of June 10, 2035.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event and not indicative of significant operational or financial news.

Positives

• The grant of stock options aligns the interests of Director Michael Heffernan with those of shareholders, as the options gain value if the company's stock price increases.
• The use of a Rule 10b5-1(c) plan demonstrates a pre-planned and transparent approach to insider transactions.

Future Outlook

The granted stock options are scheduled to fully vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders, subject to the director's continued service. This indicates a future milestone for the director's compensation.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the grant of stock options as part of executive or director compensation. Such grants are common practice across various industries, including biotechnology, to incentivize long-term performance and align management interests with shareholder value.

Corporate Governance

Related Party Transactions

• The grant of 45,000 nonstatutory stock options to Michael Thomas Heffernan, a Director of Trevi Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of options could lead to potential future dilution if exercised, but also aims to align the director's interests with shareholder value creation.
• Director (Michael Thomas Heffernan): Receives a significant equity incentive, tying his personal financial interest to the company's stock performance.

Next Steps

• The options are scheduled to vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Trevi Therapeutics, TRVI, SEC Form 4, Stock Option, Nonstatutory Stock Option, Director Compensation, Insider Transaction, Executive Compensation, Rule 10b5-1 Plan